Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …

A clear understanding of real-world uptake of nirmatrelvir–ritonavir for treatment of SARS-
CoV-2 can inform treatment allocation strategies and improve interpretation of effectiveness …

Importance With the widespread use of anti–SARS-CoV-2 drugs, accumulating data have
revealed potential viral load rebound after treatment. Objective To compare COVID-19 …

Background Oral nirmatrelvir/ritonavir is a treatment for COVID-19, but whether treatment
during the acute phase reduces the risk of developing Long COVID is unknown. Methods …

Background: Data are conflicting regarding an association between treatment of acute
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …

Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …

Background Our objective was to evaluate the real world effectiveness of
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …

Introduction Limited data exist regarding real-world utilization of nirmatrelvir/ritonavir. We
identified predictors of nirmatrelvir/ritonavir use among Veterans Affairs (VA) outpatients …

Background Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …